Long-term results with low glucose degradation product content in peritoneal dialysis fluids.
Rippe
Bengt
B
Departments of Nephrology and Physiology, University Hospital of Lund, Sweden. Bengt.Rippe@njur.lu.se
Wieslander
Anders
A
Musi
Barbara
B
D000368:Aged; D001672:Biocompatible Materials / Q000009:adverse effects; D015415:Biomarkers / Q000032:analysis; D018394:CA-125 Antigen / Q000032:analysis; D015314:Dialysis Solutions / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000009:adverse effects* / Q000378:metabolism*; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000379:methods*; D010537:Peritoneum / Q000187:drug effects* / Q000502:physiology; D011347:Procollagen / Q000032:analysis; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D001672:Biocompatible Materials; D015415:Biomarkers; D018394:CA-125 Antigen; D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D011347:Procollagen; D006820:Hyaluronic Acid; D005947:Glucose